Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00043693 · ClinicalTrials.gov registry record · NA

Family Intervention for Mental Illness and Substance Abuse

A NA study of Schizophrenia and Bipolar Disorder, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
108
Enrollment target
2
Study locations

NCT00043693: Completed NA study of Schizophrenia and Bipolar Disorder, sponsored by Dartmouth-Hitchcock Medical Center.

NCT00043693 is a NA study of Schizophrenia and Bipolar Disorder that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 108 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00043693, a NA study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
108 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate a family intervention program for individuals with bipolar disorder, schizophrenia, or schizoaffective disorder and co-occurring substance use disorders.

Interventions

  • BEHAVIORAL Family Intervention for Dual Diagnosis
  • BEHAVIORAL Family psychoeducation program

Study Locations (2)

California

  • Pacific Clinics El Camino - Santa Fe Springs

Massachusetts

  • North Suffolk Mental Health Association - Chelsea

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2002-04
Est. Completion 2008-12
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT00043693 record still lists

NCT00043693 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (51% lower).

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Family Intervention for Dual Diagnosis is the first listed.

NCT00043693 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00043693 about?

NCT00043693 is a clinical study titled "Family Intervention for Mental Illness and Substance Abuse". This study will evaluate a family intervention program for individuals with bipolar disorder, schizophrenia, or schizoaffective disorder and co-occurring substance use disorders.

What is the current status of trial NCT00043693?

This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2002-04. Estimated completion is 2008-12.

What conditions does trial NCT00043693 study?

This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder, Substance-Related Disorders.

What interventions are being tested in trial NCT00043693?

The interventions under investigation include: Family Intervention for Dual Diagnosis (BEHAVIORAL), Family psychoeducation program (BEHAVIORAL).

Who is sponsoring clinical trial NCT00043693?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00043693 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00043693's enrollment target sits among peer trials

108 130th of 315 higher than 186 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00043693, the US trial registry maintained by the National Library of Medicine. NCT00043693 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.